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The causal relationship between chronic use of bisphosphonates and occurrences of atypical
femoral fractures has not yet been established. Nonetheless, it is known that their chronic
use  is more related to fractures with a pattern differing from that of classical osteoporotic
fractures. Atypical fractures are still rare events and the beneﬁt from using bisphosphonates
remains greater for prevention and treatment of osteoporosis. There are few studies guiding
the  diagnosis and management of these fractures, thus making it difﬁcult to achieve better
results. In this report, we present the case of an elderly patient with an atypical femoral
fracture that was managed in accordance with guidance from the American Society for
Bone and Mineral Research.
© 2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
Fratura  femoral  atípica  devida  a  uso  crônico  de  bifosfonato.  Relato  de  caso
Palavras-chave:
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A relac¸ão causal entre o uso crônico dos bifosfonatos e a ocorrência de fraturas femorais
atípicas não tem sido ainda estabelecida. Todavia, sabe-se que o uso crônico dos bifosfonatos
tem  tido maior relac¸ão com fraturas com padrão diferente das clássicas fraturas osteoporóti-
cas. Fraturas atípicas são ainda eventos raros e o benefício do uso dos bifosfonatos ainda é
maior na prevenc¸ão e no tratamento da osteoporose. Pouco são os estudos que orientam o
diagnóstico e a conduc¸ão dessas fraturas, o que diﬁculta melhores resultados. Neste relatoapresentamos caso de paciente da terceira idade com fratura femoral atípica conduzida
segundo orientac¸ão da Sociedade Americana para Pesquisa Óssea e Mineral.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier Editora
Ltda. Todos os direitos reservados.
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fractures is 0.9 to 78 cases per 100,000 individuals per year.
The increase each year is two cases per 100,000 after 2 years
Table 1 – Major and minor conditions for diagnosing
atypical femoral fractures.
Major conditions Minor conditions
- Absence of any traumatic
conditions
- Femoral fracture in any
diaphyseal location: from below
the lesser trochanter to proximal
to the supracondylar region
- Transverse or short oblique
fracture
- Non-comminutive fracture
- Medial spoke in complete
-  Periosteal thickening in
the lateral cortical bone
- Indicative symptoms
- Comorbidities in
association with the use of
medications that
predispose toward fractures
- Association with bilateral
fracture and/or symptomsr e v b r a s o r t o p . 2
ntroduction
isphosphonates are today among the main types of medica-
ions prescribed worldwide for treating osteoporosis. Several
tudies have proven that they have an important role in
educing the incidence of vertebral and non-vertebral frac-
ures when used for treating senile and postmenopausal
steoporosis.1,2 The indications for using these medications
lso extend to other metabolic diseases such as bone metas-
asis, Paget’s disease and hypercalcemia.3,4 The action of
isphosphonates occurs through inhibition of the function of
steoclasts. This induces apoptosis of osteoclasts and gives
ise to signiﬁcant suppression of remodeling and consequent
oss of bone balance.5 However, the use of these medications
s not free from complications.
Several case series have already indicated that there is an
ssociation between atypical femoral fractures and prolonged
se of bisphosphonates. These fractures differ from classi-
al osteoporotic fractures in several respects, including the
echanism of action, location and fracture conﬁguration.6–8
lthough the American Society for Bone and Mineral Research
ASBMR) has published guidelines for evaluating and following
p fractures that are considered atypical, little is known about
his particular group of injuries.9 The aims of the present arti-
le were to present a case of atypical fracturing induced by
hronic use of bisphosphonates and to review the characteris-
ics, epidemiology, pathogenesis and treatment of such cases,
o as to aid orthopedic surgeons in conducting similar cases.
ase  report
he patient was a 90-year-old dark-skinned woman of weight
5 kg and height 1.50 m,  who  presented a painful condition of
echanical pattern in her right thigh that started in Novem-
er 2013. Previously, she had been able to walk within her
ommunity. She suffered involution of her gait pattern as the
ainful condition intensiﬁed and became capable of walking
nly at home, with the help of a walking frame. She did not
ave any history of falls or any local traumatic factor. She was
nown to present systemic arterial hypertension, non-insulin-
ependent diabetes mellitus, cardiopathy and osteoporosis,
hich were all being treated with drugs.
She sought the orthopedics and traumatology outpatient
linic of our service in February 2014, in order to have her com-
laint investigated. She had a history of a left-side proximal
emoral fracture 6 years previously, which had been treated
t our institution, without any complaint. She also reported
hat since then, she had been using calcium replacement and
ad kept on using bisphosphonates over the same period. She
id not present any abnormality in the clinical examination,
xcept for discomfort in her right lower limb, at thigh level
hen walking. Serial radiographs demonstrated normality
nd good evolution of the left-side fracture that had previously
een treated, but with arching of the femoral cortical bone and
clerosis of the lateral wall in its middle third. In the light of
hese ﬁndings, magnetic resonance imaging of the thigh was
equested. This showed the presence of incomplete fractur-
ng of the posterolateral/lateral cortical bone with thickening;5 0(4):482–485 483
of the adjacent cortical bone and bone edema, in association
with slight unilamellar periosteal thickening. Investigation of
laboratory parameters did not show any associated metabolic
abnormality (Fig. 1).
Given these factors and the symptomatic condition, a sur-
gical approach was indicated. There was discussion regarding
the best ﬁxation method: intramedullary ﬁxation using a
cephalomedullary nail or ﬁxation using a plate. In this speciﬁc
case, an initial attempt was made to use an intramedullary
nail, but because of diaphyseal arching and the risk of wors-
ening the existing fracture, it was decided to place a locked
plate as a bridge.
Today, the patient presents 4 months of postoperative evo-
lution, with involution of the symptomatic condition and
improvement of the gait pattern, and without any complaints.
She already presents radiological indications of fracture con-
solidation (Fig. 2). Because of the history of a previous proximal
femoral fracture and the atypical fracture induced by bis-
phosphonates (high risk of new fractures), it was decided
to maintain the supplementation of calcium and vitamin D,
withdraw the use of bisphosphonates and start the patient on
denosumab.
Discussion
Because of the lack of criteria for deﬁning atypical femoral
fractures, the ASBMR has established major and minor
conditions for diagnosing these fractures. The presence of
the major conditions is fundamental for designating the
fracture as atypical and distinguishing it from osteoporotic
fractures, while the minor conditions may be associated
with atypical fractures but are not fundamental (Table 1).9
Atypical femoral fractures have been correlated with several
factors, including Asian ancestry, bilateral fractures, indica-
tive signs and symptoms, chronic use of corticosteroids and
proton pump inhibitors, vitamin D deﬁciency and presence
of diabetes mellitus and rheumatoid arthritis.7,8 The ASBMR
has estimated that the accumulated incidence of atypicalfractures; fractures that involve
only the lateral cortical bone in
incomplete cases
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Fig. 1 – Preoperative radiological evaluation. (a, b) Radiographic images showing area of sclerosis in the middle third and
synthesis material from previous femoral fracture and (c, d) magnetic resonance imaging slices showing area of incomplete
 edemfracture in the posterolateral cortical bone, with permeating
of use of bisphosphonates and this rises to 78 per 1,000,000
every year after 8 years of use of this medication.9
Several pathogenic mechanisms that explain the relation-
ship between chronic use of bisphosphonates and atypical
femoral fractures have been studied. Chronic use is respon-
sible for the deleterious effect on bone quality, because this
inhibits bone remodeling at cell level. Although increased
remodeling predisposes toward bone fragility, this effect
Fig. 2 – Late-stage postoperative radiological evaluation (3 month
and oblique view (b, c).a.
also contributes toward an accumulation of architectural
damage, reduction of the heterogeneity of the cell matrix,
increased glycation of the ﬁnal products and losses through
remodeling.1,2,7–9 After a condition of atypical femoral frac-
ture has been diagnosed, use of bisphosphonates should be
halted. The idea of vitamin D and calcium supplementation
should be evaluated; introduction of bone anabolic agents
should be considered (denosumab or teriparatide); laboratory
s) showing consolidation in anteroposterior (AP) view (a)
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ests should be used to identify any existence of predisposing
etabolic conditions; the contralateral side should be eval-
ated, given that the risk of bilaterality is 28–44.2%; and
astly, the best ﬁxation method should be evaluated.8,9 No
ontrolled studies comparing ﬁxation with plates and screws
n relation to intramedullary ﬁxation have been conducted,
lthough the latter has the theoretical beneﬁt of presenting
onsolidation through endochondral repair. Therefore, there
s a certain degree of preference for using nails for treat-
ng atypical femoral fractures.8–10 Despite all the care that is
aken today, and the better knowledge available, the progno-
is for these fractures is still poor, with descriptions of the
eed to repeat the procedure in up to 44% of the cases in
ome studies. The time taken for consolidation to be achieved
hat has been described in the literature ranges from 12 to
0 months.
The screening for evaluating bone abnormalities in all
atients receiving bisphosphonates is inadequate because
f the low incidence rate of these fractures and because
adiological abnormalities are often unidentiﬁable. Never-
heless, in view of the presence of pain of mechanical
attern in patients who  make chronic use of bisphosphonates,
areful assessment needs to be made using serial radiolog-
cal imaging, scintigraphy and magnetic resonance imaging,
n order to institute early diagnosis and treatment.5,8–10
ecause many  questions relating to atypical femoral frac-
ures still do not have answers, further studies aiming toward
etter histomorphometric and bone biomechanical evalu-
tions and the relationship of these fractures to certain
edications are fundamental. Moreover, discussion toward
reating a national register of atypical femoral fractures
ill ensure better understanding and discussion of these
ases.onﬂicts  of  interest
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